Clinical guideline on the management of the patient with dyspepsia;Guía de práctica clínica sobre el manejo del paciente con dispepsia

Gastroenterologia y Hepatologia

Volumn 26, Issue 9, 2003, Pages 571-613

  Mascort, J J ^a   Marzo, M ^b   Alonso Coello, P ^b   Barenys, M ^c   Carballo, F ^c   Fernandez M ^b   Ferrandiz L J ^a   Bonfill, X ^b   Pique J M ^c  

^a Soc Espanola de Med de Fam y Com

^b Centro Cochrane Iberoamericano   (Spain)

^c Asoc Espanola de Gastroenterologia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; CISAPRIDE; CLARITHROMYCIN; DOMPERIDONE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; METRONIDAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; STOMACH SECRETION INHIBITOR; TETRACYCLINE; TRANQUILIZER;

ABDOMINAL PAIN; ALGORITHM; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HUMAN; NAUSEA; PRACTICE GUIDELINE; PREVALENCE; RADIODIAGNOSIS; REVIEW; RISK FACTOR; SYMPTOMATOLOGY;

EID: 0348231946     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13054452     Document Type: Review

References (233)

1. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45 (Supl. 2): 37-42.
2. Institute for Clinical Systems Improvement. Health Care Guideline: Dyspepsia. Institute for Clinical Systems Improvement, 2002. http://www.icsi.org/guide/Dyspep.pdf
3. Aymerich M, Baena JM, Boix C, Carrillo R, Madrilejos R, Mascort JJ et al. Direcció clínica en l'atenció primària. Dispepsia - H. pylori. Guies de pràctica clínica i material docent. http://www.gencat.net/ics/professionals/guies/dispepsia/dispepsia.htm
4. Agreus L. Natural history of dyspepsia. Gut 2002; 50 (Supl. 4): 2-9.
5. Grupo de trabajo de la guía de práctica clínica sobre ERGE. Manejo del paciente con enfermedad por reflujo gastroesofá gico (ERGE). Guía de práctica clínica. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2001. Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 1. http://www.guiasgastro.net
6. Veldhuyzen van Zanten SJO, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M et al, for the Canadian Dyspepsia Working Group. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. CMAJ 2000; 162 (Supl. 12): 3-23.
7. Kellow JE. Organic causes of dyspepsia, and discriminating functional from organic dyspepsia. Best Pract Res Clin Gastroenterol 2001; 15: 477-487.
8. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl 1999; 231: 3-8.
9. SBU - The Swedish Council on Technology Assessment in Health Care. Stomach pain - evidence-based methods in the diagnosis and treatment of dyspepsia. Stockholm, 2000.
10. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 20-28.
11. Caballero Plasencia AM, Sofos Kontoyannis S, Martín Ruiz JL, Valenzuela Barranco M. La prevalencia de la dispepsia en España. Med Clin (Barc) 1994; 103: 717.
12. Schwartz MD. Dyspepsia, peptic ulcer disease, and esophageal reflux disease. West J Med 2002; 176: 98-103.
13. Turabian JL, Gutiérrez V. Variaciones en la frecuencia de las enfermedades crónicas y los factores de riesgo en atención primaria: 1985-1995. Aten Primaria 1996; 18: 65-69.
14. Talley NJ. Dyspepsia: management guidelines for the millennium. Gut 2002; 50 (Supl. 4): 72-78.
15. Bazaldua OV, Schneider FD. Evaluation and management of dyspepsia. Am Fam Physician 1999; 60: 1.773-1.788.
16. Haycox A, Einarson T, Eggleston A. The health economic impact of upper gastrointestinal symptoms in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 38-47.
17. Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtmann G. AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998; 114: 582-595.
18. Fisher RS, Parkman HP. Management of non ulcer dyspepsia. N Engl J Med 1998; 339: 1.376-1.381.
19. Barenys M, Abad A, Pons JM, Moreno V, Rota R, Granados A et al. Scoring system has better discriminative value than Helicobacter pylori testing in patients with dyspepsia in a setting with high prevalence of infection. Eur J Gastroenterol Hepatol 2000; 12: 1.275-1.282.
20. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, Version 1.0.IARC Cancer Base n.° 5. Lyon, IARC Press, 2001. Limited version available from: http://www-dep.iarc.fr/globocan/globocan.htm. Last updated on 03/02/2001.
21. Moayyedi P, Mason J. Clinical and economic consequences of dyspepsia in the community. Gut 2002; 50 (Supl. 4): 10-12.
22. Ruiz M, Vilasante F, León F, González-Lara V, González C, Crespo M et al. Cuestionario sobre calidad de vida asociada a dispepsia. Adaptación española y validación del cuestionario Dyspepsia Related Health Scale. Med Clin (Barc) 2001; 117: 567-573.
23. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 48-54.
24. Olden KW. Are psychosocial factors of aetiological importance in functional dyspepsia? Baillieres Clin Gastroenterol 1998; 12: 557-571.
25. Olden KW, Drossman DA. Psychologic and psychiatric aspects of gastrointestinal disease. Med Clin North Am 2000; 84: 1.313-1.327.
26. Kay L, Jorgensen T. Epidemiology of upper dyspepsia in random population. Prevalence, incidence, natural history and risk factors. Scan J Gastroenterol 1994; 29: 1-7.
27. Yuyuan LI, Yuqiang NIE, Weihong SHA, Hua SU. The link between social psychosocial and functional dyspepsia: An epidemiological study. Chin Med J 2002; 115: 1.082-1.084.
28. Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 29-37.
29. Pantoflickova D, Blum AL, Koelz HR. Helicobacter pylori and functional dyspepsia: a real causal link? Bailleres Clin Gastroenterol 1998; 12: 503-532.
30. Danesh J, Lawrence M, Murphy M, Roberts S, Collins R. Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia. Arch Intern Med 2000; 160: 1.192-1.198.
31. Bazzoli F, De Luca L, Pozzato P, Zagari RM, Fossi S, Ricciardiello L et al. Helicobacter pylori and functional dyspepsia: review of previous studies and commentary on new data. Gut 2002; 50 (Supl. 4): 33-35.
32. Elta GH, Behler EM, Colturi TJ. Comparison of coffee intake and coffee-induced symptoms in patients with duodenal ulcer, nonulcer dyspepsia, and normal controls. Am J Gastroenterol 1990; 85: 1.339-1.342.
33. Nandurkar S, Talley NJ, Xia H, Mitchell H., Hazel S, Jones M. Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. Arch Intern Med 1998; 158: 1.427-1.433.
34. Woodward M, Morrison CE, McColl Ke. The prevalence of dyspepsia and use of antisecretory medicatioin in North Gasgow: role of Helicobacter pylori vs lifestyle factors. Aliment Pharmacol 1999; 13: 1.505-1.509.
35. Bytzer P, Howell S, Leemon M, Young LJ, Jones MP, Talley NJ. Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms: a population based study in 15000 Australian adults. Gut 2001; 49: 66-67.
36. Talley NJ, Weaver AL, Zinsmeister AR. Smoking, alcohol, and nonsteroidal anti-inflammatory drugs in outpatients with functional dyspepsia and among dyspepsia subgroups. Am J Gastroenterol 1994; 89: 524-528.
37. Talley NJ, McNeil D, Piper DW. Environmental factors and chronic unexplained dyspepsia. Association with acetaminophen but not other analgesics, alcohol, coffee, tea, or smoking. Dig Dis Sci 1988; 33: 641-648.
38. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997; 24: 2-17.
39. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
40. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal antiinflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13.
41. Straus WL, Ofman JJ, MacLean C, Morton S, Berger ML, Roth EA et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroentrol 2002; 97: 1.951-1.958.
42. Aalykke C, Lauritsen K. Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001; 15: 705-722.
43. The National Prescribing Center. Managing dyspepsia: the role of Helicobacter pylori. MeReC Bulletin 2001; 12 (1): 1-4.
44. Moayyedi P, Axon AT, Feltbower R, Duffett S, Crocombe W, Braunholtz D et al. Relation of adult lifestiles and socioeconomic factors to the prevalence of Helicobacter pylori infection. Int J Epidemiol 2002; 31: 624-631.
45. Goodwin RD, Murray BS. Generalized Anxiety disorder and peptic ulcer disease among adults in the United States. Psychosomatic Medicine 2002; 64: 862-866.
46. Andersen IB, Jorgensen T, Bonnevie O, Gronbaek M, Sorensen TI. Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population-based cohort study. Epidemiology 2000; 11: 434-439.
47. International Agency for Research on Cancer. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 177-240.
48. Correa P. Gastric neoplasia. Curr Gastroenterol Rep 2002; 4: 463-470.
49. Priebe WM, DaCosta LR, Beck IT. Is epigastric tenderness a sign of peptic ulcer disease? Gastroenterology 1982; 82: 16-19.
50. Numans ME, Van der Graaf Y, de Wit NJ, Touw-Otten F, de Melker RA. How much ulcer is ulcer-like? Diagnostic determinants of peptic ulcer in open access gastroscopy. Fam Pract 1994; 11: 382-388.
51. Johannessen T, Petersen H, Kleveland PM, Dybdahl JH, Sandvik AK, Brenna E et al. The predictive value of history in dyspepsia. Scand J Gastroenterol 1990; 25: 689-697.
52. Muris JW, Starmans R, Pop P, Crebolder HF, Knottnerus JA. Discriminant value of symptoms in patients with dyspepsia. J Fam Pract 1994; 38: 139-143.
53. Bytzer P, Hansen JM, Havelund T, Malchow-Moller A, Schaffalitzky de Muckadell OB. Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement. Eur J Gastroenterol Hepatol 1996; 8: 359-363.
54. Hansen JM, Bytzer P, Schaffalitzky De Muckadell OB. Management of dyspeptic patients in primary care. Value of the unaided clinical diagnosis and of dyspepsia subgrouping. Scand J Gastroenterol 1998; 33: 799-805.
55. Bustamante M, Ferrando MJ, Devesa F, Borghol A. Predicción del diagnóstico endoscópico en el paciente con dispepsia: valor del síntoma predominante de presentación y de la presunción clínica inicial. Gastroenterol Hepatol 2000; 23: 66-70.
56. Heikkinen M, Pikkarainen P, Eskelinen M, Julkunen R. GPs' ability to diagnose dyspepsia based only on physical examination and patient history. Scand J Prim Health Care 2000; 18: 99-104.
57. Danish dyspepsia study group. Value of the unaided clinical diagnosis in dyspeptic patients in primary care. Am J Gastroenterol 2001; 96: 1.417-1.421.
58. Heading RC, Wager E, Tooley PJ. Reliability of symptom assessment in dyspepsia. Eur J Gastroenterol Hepatol 1997; 9: 779-781.
59. Westbrook JI, McIntosh JH, Duggan JM. Accuracy of provisional diagnoses of dyspepsia in patients undergoing first endoscopy. Gastrointest Endosc 2001; 53: 283-288.
60. Barenys M, Rota R, Moreno V, Villafafila R, García-Bayo I, Abad A et al. Validación prospectiva de un modelo clínico predictivo de dispepsia orgánica en el ámbito de la atención primaria y de las consultas de gastroenterología (Abstract). astroenterol Hepatol 2003; 26 (2): 103.
61. Talley NJ, Weaver AL, Tesmer DL, Zinsmeister AR. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993; 105: 1.378-1.386.
62. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1.259-1.268.
63. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 671-680.
64. Holtmann G, Stanghellini V, Talley NJ. Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: clarifying the concepts. Baillieres Clin Gastroenterol 1998; 12: 417-433.
65. Hession PT, Malagelada J. Review article: the initial management of uninvestigated dyspepsia in younger patients - the value of symptom-guided strategies should be reconsidered. Aliment Pharmacol Ther 2000; 14: 379-388.
66. Madsen LG, Bytzer P. The value of alarm features in identifying organic causes of dyspepsia. Can J Gastroenterol 2000; 14: 713-720.
67. Scottish Intercollegiate Guideline Network (SIGN). Dyspepsia. Edimburgh: SIGN, 2003 [en prensa].
68. Alberta Clinical Practice Guideline Working Group. Guideline for Diagnosis and Treatment of Chronic Undiagnosed Dyspepsia in Adults. The Alberta Clinical Guideline Program. June, 2000.
69. Bristish Gastroenterology Society. Dyspepsia Management Guidelines. Londres: The Society, 2002. http://www.bsg.org.uk/pdf_word_docs/dyspepsia.doc
70. Adang RP, Ambergen AW, Talmon JL, Hasman A, Vismans JF, Stockbrugger RW. The discriminative value of patient characteristics and dyspeptic symptoms for upper gastrointestinal endoscopic findings: a study on the clinical presentation of 1,147 patients. Digestion 1996; 57: 118-134.
71. Wallace MB, Durkalski VL, Vaughan J, Palesch YY, Libby ED, Jowell PS et al. Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study. Gut 2001; 49: 29-34.
72. Williams B, Luckas M, Ellingham JH, Dain A, Wicks AC. Do young patients with dyspepsia need investigation? Lancet 1988; 2: 1.349-1.351.
73. Christie J, Shepherd NA, Codling BW, Valori RM. Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia. Gut 1997; 41: 513-517.
74. Gillen D, McColl KE. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999; 94: 75-79.
75. Heaney A, Collins JS, Tham TC, Watson PR, McFarland JR, Bamford KB. A prospective study of the management of the young Helicobacter pylori negative dyspeptic patient can gastroscopies be saved in clinical practice? Eur J Gastroenterol Hepatol 1998; 10: 953-956.
76. Canga C 3rd, Vakil N. Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy. Am J Gastroenterol 2002; 97: 600-603.
77. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 1998; 114: 579_581.
78. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A et al. The European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000. Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180.
79. Ofman JJ, Rabeneck L. The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review. Am J Med 1999; 106: 335-346.
80. Cardin F, Zorzi M, Furlanetto A, Guerra C, Bandini F, Polito D et al. Are dyspepsia management guidelines coherent with primary care practice? Scand J Gastroenterol 2002; 37: 1.269-1.275.
81. Hallissey MT, Allum WH, Jewkes AJ, Ellis DJ, Fielding JW. Early detection of gastric cancer. BMJ 1990; 301: 513-515.
82. Sue-Ling HM, Johnston D, Martin IG, Dixon MF, Lansdown MR, McMahon MJ et al. Gastric cancer: a curable disease in Britain. BMJ 1993; 307: 591-596.
83. Bustamante M, Devesa F, Borghol A, Fernando MJ. Influencia de la edad en el diagnóstico endoscópico de los pacientes con dispepsia no complicada. Rev Sdad Valenciana Patol Dig 2001; 20: 1-6.
84. Breslin NP, Thomson AB, Bailey RJ, Blustein PK, Meddings J, Lalor E et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut 2000; 46: 93-97.
85. Martin IG, Young S, Sue-Ling HM, Johnston D. Delays in the diagnosis of oesophagogastric cancer: a consecutive case series. BMJ 1997; 314: 467-470.
86. Griffin SM, Raimes SA. Proton pump inhibitors may mask early gastric cancer. Dyspeptic patients over 45 should undergo endoscopy before thesedrugs are started. BMJ 1998; 317: 1.606-1.607.
87. Suvakovic Z, Bramble MG, Jones R, Wilson C, Idle N, Ryott J. Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study. Gut 1997; 41: 308-313.
88. Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000; 46: 464-467.
89. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet 2000; 356: 455-460.
90. Laheij RJ, Severens JL, Van de Lisdonk EH, Verbeek AL, Jansen JB. Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis. Aliment Pharmacol Ther 1998; 12: 1.249-1.256.
91. Pajares JM. Helicobacter pylori infection and gastric cancer in Spain. Hepatogastroenterology 2001; 48: 1.556-1.559.
92. NHS Executive Referral Guidelines for Suspected Cancer. Londres: HMSO, 2000.
93. Allum WH, Griffin SM, Watson A, Colin-Jones D. Guidelines for the management of oesophageal and gastric cancer. Gut 2002 (Supl. 5): 1-23.
94. Buckley MJ, Scanlon C, McGurgan P, O'Morain CA. A validated dyspepsia symptom score. Ital J Gastroenterol Hepatol 1997; 29: 495-500.
95. Mendall MA, Jazrawi RP, Marrero JM, Molineaux N, Levi J, Maxwell JD et al. Serology for Helicobacter pylori compared with symptom questionnaires in screening before direct access endoscopy. Gut 1995; 36: 330-333.
96. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB, Malchow-Moller A. Predicting endoscopic diagnosis in the dyspeptic patient. The value of predictive score models. Scand J Gastroenterol 1997; 32: 118-125.
97. Coelho-Filho JM, Lima JW, Furtado GB, Castelo A. Development of a strategy to optimize the indications for the upper gastrointestinal endoscopy in patients with dyspepsia at the primary care level. Rev Assoc Med Bras 2000; 46: 30-38.
98. Martín de Argila C, Boixeda D, Canton R, Mir N, de Rafael L, Gisbert J et al. Helicobacter pylori infection in a healthy population in Spain. Eur J Gastroenterol Hepatol 1996; 8: 1.165-1.168.
99. Cilla G, Pérez-Trallero E, García-Bengoechea M, Marimón JM, Arenas JI. Helicobacter pylori infection: a seroepidemiological study in Gipuzkoa, Basque Country, Spain. Eur J Epidemiol 1997; 13: 945-949.
100. Caballero AM, Kotoyannis S, Valenzuela M, Casado FJ, Guilarte J. Epidemiología de la dispepsia en una población aleatoria mediterránea. Prevalencia de la infección por Helicobacter pylori. Rev Esp Enferm Dig 2000; 92: 781-792.
101. García M, Martí J, León I, Muñiz D, Teruel J, Baena JM et al. Prevalencia de la infección por Helicobacter pylori en atención primaria: estudio seroepidemiológico. Aten Primaria 2002; 29: 553-557.
102. Smoot DT, Go MF, Cryer B. Peptic ulcer disease. Prim Care 2001; 28: 487-503.
103. Bodger K, Daly MJ, Heatley RV. Prescribing patterns for dyspepsia in primary care: a prospective study of selected general practitioners. Aliment Pharmacol Ther 1996; 10: 889-895.
104. Folkersen BH, Larsen B, Qvist P. General practitioners' handling of patients with dyspepsia. Ugeskr Laeger 1997; 159: 3.777-3.781 [resumen].
105. Martínez-Sánchez G, Saperas E, Benavent J, Mearin F, Pinol JL, Barenys M et al. Actitud de los médicos de atención primaria del área metropolitana de Barcelona frente al diagnóstico y tratamiento de la infección por Helicobacter pylori en enfermedades gastroduodenales. Gastroenterol Hepatol 1998; 21: 473-478.
106. Gené E, Calvet X, Azagra R, López T, Cubells MJ. Manejo de la dispepsia, la enfermedad ulcerosa y la infección por Helicobacter pylori en atención primaria. Aten Primaria 2002; 29: 486-494.
107. Weijnen CF, de Wit NJ, Numans ME, Quartero AO, Verheij TJ. Dyspepsia management in primary care in the Netherlands: to what extent is Helicobacter pylori diagnosis and treatment incorporated? Results from a survey among general practitioners in the Netherlands. Digestion 2001; 64: 40-45.
108. Meineche-Schmidt V, Fly G. Helicobacter pylori test-and-treat strategy in dyspepsia patients in general practice. Too many patients to treat? Gut 1999; 43 (Supl.): A355.
109. Delaney B, Moayyedi P, Deeks J, Innes M, Soo S, Barton P et al. The management of dyspepsia: a systematic review. Health Technol Assess 2000; 4 (39). http://www.ncchta.org/fullmono/mon439.pdf
110. Delaney BC, Innes MA, Deeks J, Wilson S, Cooner MK, Moayyedi P et al. Initial management strategies for dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software.
111. Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002; 122: 1.270-1.285.
112. National Institute for Clinical Excellence. Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia. Londres: National Institute for Clinical. Excellence (NICE). Technology Appraisal, 2000.
113. Quartero AO, Numans ME, de Melker RA, Hoes AW, de Wit NJ. Dyspepsia in primary care: acid suppression as effective as prokinetic therapy. A randomized clinical trial. Scand J Gastroenterol 2001; 36: 942-947.
114. Ghosh S, Kinnear M. Dyspepsia in primary care to prescribe or to investigate? Br J Gen Pract 2001; 51: 612-614.
115. Hession PT, Malagelada J. Review article: the initial management of uninvestigated dyspepsia in younger patients - the value of symptom-guided strategies should be reconsidered. Aliment Pharmacol Ther 2000; 14: 379-388.
116. Lewin van den Broek NT, Numans ME, Buskens E, Verheij TJ, de Wit NJ, Smout AJ. A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome. Br J Gen Pract 2001; 51: 619-624.
117. Ofman JJ, Rabeneck L. The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review. Am J Med 1999; 106: 335-346.
118. Rabeneck L, Souchek J, Wristers K, Menke T, Ambriz E, Huang I et al. A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia. Am J Gastroenterol 2002; 97: 3.045-3.051.
119. Brignoli R, Watkins P, Halter F. The Omega-Project - a comparison of two diagnostic strategies for risk - and cost-oriented management of dyspepsia. Eur J Gastroenterol Hepatol 1997; 9: 337-343.
120. Gisbert JP, Pajares JM. Helicobacter pylori "test-and-scope" strategy for dyspeptic patients. Helicobacter 2000; 2: 57-68.
121. Sobala GM, Crabtree JE, Pentith JA, Rathbone BJ, Shallcross TM, Wyatt JI et al. Screening dyspepsia by serology to Helicobacter pylori. Lancet 1991; 338: 94-96.
122. Patel P, Khulusi S, Mendall MA, Lloyd R, Jazrawi R, Maxwell JD et al. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet 1995; 346: 1.315-1.318.
123. Delaney BC, Wilson S, Roalfe A, Roberts L, Redman V, Wearn A et al. Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care. BMJ 2001; 322: 898-901.
124. Rubin G, Meineche-Schmidt V, Roberts A, de Wit N. The use of consensus to develop guidelines for the management of Helicobacter pylori infection in primary care. Fam Pract 2000; 17 (Supl. 2): 21-26.
125. The European Helicobacter Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
126. Jones R, Tait C, Sladen G, Weston-Baker J. A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice. Int J Clin Pract 1999; 53: 413-416.
127. Heaney A, Collins JS, Watson RG, McFarland RJ, Bamford KB, Tham TC. A prospective randomised trial of a "test and treat" policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999; 45: 186-190.
128. McColl KE, Murray LS, Gillen D, Walker A, Wirz A, Fletcher J et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia. BMJ 2002; 324: 999-1.002.
129. Gisbert JP, Pajares JM. Helicobacter pylori "test-and-treat" strategy for dyspeptic patients. Scand J Gastroenterol 1999; 7: 644-652.
130. Morris AJ, Craig CF, Morran C, Burns H, Harden K, Power A et al. The influence of H. pylori status on symptoms and quality of life in patients receiving maintenance acid suppression therapy. UEGW. Amsterdam, 2001. 9th United European Gastroenterology, octubre de 2001.
131. Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002; 324: 1.012-1.016.
132. Scottish Intercollegiate Guideline Network (SIGN). UPDATE H. pylori: eradication therapy in dyspeptic disease. Edimburgo: SIGN, 1999.
133. De Wit NJ, Quartero AO, Numans ME. Helicobacter pylori treatment instead of maintenance therapy for peptic ulcer disease: the effectiveness of case-finding in general practice. Aliment Pharmacol Ther 1999; 13: 1.317-1.321.
134. Khan Z, Nair P, O'Shea C, Spiers N, Playford RJ, Wicks AC. Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study. Scand J Gastroenterol 2002; 37: 144-147.
135. Meineche-Schmidt V, Rubin G, de Wit NJ. Helicobacter pylori infection: a comparative review of existing management guidelines. Fam Pract 2000; 17 (Supl. 2): 2-5.
136. Weijnen CF, Numans ME, de Wit NJ, Smout AJ, Moons KG, Verheij TJ et al. Testing for Helicobacter pylori in dyspeptic patients suspected of peptic ulcer disease in primary care: cross sectional study. BMJ 2001; 323: 71-75.
137. Kolk H, Maaroos HI, Kull I, Labotkin K, Loivukene K, Mikelsaar M. Open access endoscopy in an epidemiological situation of high prevalence of Helicobacter pylori infection: applicability of the guidelines of the European Society for Primary Care Gastroenterology. Fam Pract 2002; 19: 231-235.
138. Harvey RF, Spence RW, Lane JA, Nair P, Murray LJ, Harvey IM et al. Relationship between the birth cohort pattern of Helicobacter pylori infection and the epidemiology of duodenal ulcer. QJM 2002; 95: 519-525.
139. Management of upper dyspepsia in general practice (funded by DACEHTA). Primary Research (project). Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). http://www.dihta.dk/projekter/230_uk.asp
140. Gisbert JP, Khorrami, S Badia X, Pajares JM. La estrategia "test and treat" (diagnosticar y tratar la infección por Helicobacter pylori) ante el paciente dispéptico en Atención Primaria. Club Español para el estudio del Helicobacter pylori. http://www.sepd.org/gaceta/hpclub.htm
141. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994; 343: 811-816.
142. Delaney BC, Wilson S, Roalfe A, Roberts L, Redman V, Wearn A et al. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care. Lancet 2000; 356: 1.965-1.969.
143. Marshall JK, Armstrong D, O'Brien BJ. Test and treat strategies for Helicobacter pylori in uninvestigated dyspepsia: a Canadian economic analysis. Can J Gastroenterol 2000; 14: 379-388.
144. Briggs AH, Sculpher MJ, Logan RP, Aldous J, Ramsay ME, Baron JH. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ 1996; 312: 1321-5.
145. Moayyedi P, Mason J, Zilles A, Axon ATR, Chalmers DM, Drummond MF. Screening and treating for H. pylori-Is it cost-effective in clinical practice? Digestion 1998; 59 (Supl. 3): 10.
146. Sonnenberg A. What to do about Helicobacter pylori? A decision analysis of its implication on public health. Helicobacter 2002; 7: 60-66.
147. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. J Fam Pract 1997; 44: 545-555.
148. Moayyedi P. Helicobacter pylori test and treat strategy for young dyspeptic patients: new data. Gut 2002; 50 (Supl. 4): 47-50.
149. García-Altés A, Rota R, Barenys M, Abad A. "Test and treat" and endoscopy are the most cost-effective strategies for the management of dyspepsia depending on the age of the patient. 18th Annual Meeting of the International Society of Technology Assessment in Health Care. ISTAHC. Berlin: 2002.
150. Dooley CP, Larson AW, Stace NH, Renner IG, Valenzuela JE, Eliasoph J et al. Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study. Ann Intern Med 1984; 101: 538-545.
151. Galloway JM, Gibson J, Dalrymple J. Endoscopy in primary care: a survey of current practice. Br J Gen Pract 2002; 52: 536-538.
152. Shaw PC, van Romunde LK, Griffioen G, Janssens AR, Kreuning J, Eilers GA. Peptic ulcer and gastric carcinoma: diagnosis with biphasic radiography compared with fiberoptic endoscopy. Radiology 1987; 163: 39-42.
153. Shaw PC, Romunde IKI, Griffioen G, Janssens AR, Kreuning J, Lamers CBHW. Detection of gastric erosions: comparison of biphasic radiography with fiberoptic endoscopy. Radiology 1991; 178: 63-66.
154. a ed. Londres: The Royal College of Radiologists, 1998.
155. Logan RP, Walker MM. ABC of the upper gastrointestinal tract: epidemiology and diagnosis of Helicobacter pylori infection. BMJ 2001; 323: 920-922.
156. Meurer LN, Bower DJ. Management of Helicobacter pylori infection. Am Fam Physician 2002; 65: 1.327-1.336.
157. Roberts AP, Childs SM, Rubin G, de Wit NJ. Tests for Helicobacter pylori infection: a critical appraisal from primary care. Fam Pract 2000; 17 (Supl. 2): 12-20.
158. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996; 91: 1.138-1.144.
159. Stevens M, Livsey S, Swann R. Evaluation of sixteen EIAs for the detection of antibodies to Helicobacter pylori. Londres: Department of Health, 1997; 1-46.
160. Laheij RJ, Straatman H, Jansen JB, Verbeek AL. Evaluation of commercially available Helicobacter pylori serology kits: a review. J Clin Microbiol 1998; 36: 2.803-2.809.
161. Vaira D, Vakil N. Blood, urine, stool, breath, money, and Helicobacter pylori. Gut 2001; 48: 287.
162. Gisbert JP, Pajares JM. Serología "rápida" para el diagnóstico de la infección por H. Pylori, ¿puede recomendarse su empleo sistemático en la práctica clínica? Med Clin (Barc) 2002; 118: 196-197.
163. Gisbert JP, Pajares JM. Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review. Am J Gastroenterol 2001; 96: 2.829-2.838.
164. Vakil N, Rhew D, Soll A, Ofman JJ. The cost-effectiveness of diagnostic testing strategies for H. pylori. Am J Gastroenterol 2000; 95: 1.691-1.698.
165. Savarino V, Bisso G, Pivari M, Zentilin P, Bilardi C, Dulbecco P et al. Effect of gastric acid suppression on 13C-urea breath test: comparison of ranitidine with omeprazole. Aliment Pharmacol Ther 2000; 14: 291-297.
166. Savarino V, Tracci D, Dulbecco P, Mele MR, Zentilin P, Mansi C et al. Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori. Am J Gastroenterol 2001; 96: 348-352.
167. Connor SJ, Seow F, Ngu MC, Katelaris PH. The effect of dosing with omeprazole on the accuracy of the 13C-urea breath test in Helicobacter pylori-infected subjects. Aliment Pharmacol Ther 1999; 13: 1.287-1.293.
168. Connor SJ, Ngu MC, Katelaris PH. The impact of short-term ranitidine use on the precision of the 13C-urea breath test in subjects infected with Helicobacter pylori. Eur J Gastroenterol Hepatol 1999; 11: 1.135-1.138.
169. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998; 129: 547-550.
170. Gisbert JP, Cabrera MM, Pajares JM. Detección del antígeno de Helicobacter pylori en heces para el diagnóstico inicial de la infección y para la confirmación de su erradicación tras el tratamiento. Med Clin (Barc) 2002; 118: 401-404.
171. Schmulson MJ, Mayer EA. Gastrointestinal sensory abnormalities in functional dyspepsia. Baillieres Clin Gastroenterol 1998; 12: 545-556.
172. Malagelada JR. Functional dyspepsia. Insights on mechanisms and management strategies. Gastroenterol Clin North Am 1996; 25: 103-112.
173. Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software.
174. Finney FS, Kinnersley N, Hughes M, O'Bryan-Tear CG, Lothian J. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998; 26: 312-320.
175. Allescher HD, Bockenhoff A, Knapp G, Wienbeck M, Hartung J. Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001; 36: 934-941.
176. 2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001; 15: 1.291-1.299.
177. Shiau JY, Vijay K, Shula B, Dubé C. The efficacy of proton pump inhibitors in adults with functional dyspepsia. Ottawwa: Canadian Coordinating Office for Health Technology Assessment, 2002. Technology report n.° 22.
178. Talley NJ, Lauritsen K. The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut 2002; 50 (Supl. 4): 36-41.
179. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR. The Frosch Study Group. Short course acid suppesive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. Gut 2000; 47: 473-480.
180. Shukla VK, Otten N, Dubé C, Moher D. Use of cisapride in patients with non-ulcer dyspepsia: a meta-analysis of randomized trials. Ottawwa: Canadian Coordinating Office for Health Technology Assessment, 2000.
181. Sander JO, Veldhuyzen van Zanten SJO, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 689-696.
182. Cisaprida for non ulcer dyspepsia. Bandolier 2000; junio: 76-73. http://www.jr2.ox.ac.uk/bandolier/band76/b76-3.html
183. Arienti V, Corazza GR, Sorge M, Boriani L, Ugenti F, Biagi F et al. The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia. Aliment Pharmacol Ther 1994; 8: 631-638.
184. Corazza GR, Biagi F, Albano O, Porro GB, Cheli R, Mazzacca G et al. Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial. Ital J Gastroenterol 1996; 28: 317-323.
185. Song CW, Chun HJ, Kim CD, Ryu HS, Choe JG, Hyun JH. Effects of levosulpiride in patients with functional dyspepsia accompanied by delayed gastric emptying. Korean J Intern Med 1998; 13: 15-21.
186. Mansi C, Borro P, Giacomini M, Biagini R, Mele MR, Pandolfo N et al. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000; 14: 561-569.
187. Hallerback BI, Bommelaer G, Bredberg E, Campbell M, Hellblom M, Lauritsen K et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002; 5: 959-967.
188. Soo S, Moayyedi P, Deeks J, Delaney B, Lewis M, Forman D. Psychological interventions for non-ulcer dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software.
189. Jackson JL, O'Malley PG, Tomkins G, Baldin E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72.
190. Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ. Long-term improvement in functional dispepsia using hypnoterapy. Gastroenterology 2002; 123: 1.778-1.785.
191. Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis BMJ 1999; 319: 1.040-1.044.
192. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 134: 361-369.
193. Gisbert JP, Calvet X, Gabriel R, Pajares JM. Infección por Helicobacter pylori y dispepsia funcional. Metaanálisis de la eficacia del tratamiento erradicador. Med Clin (Barc) 2002; 118: 405-409.
194. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software.
195. Cartas BMJ. http://bmj.com/cgi/eletters/319/7216/1040
196. Hsu PI, Lai KH, Tseng HH, Lo GH, Lo CC, Lin CK et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 195-201.
197. Koelz HR, Arnold R, Stolte M, Fischer M, Blum AL; The Frosch Study Group. Treatment of Helicobacter pylori in functional dispepsia resistant to conventional management: a double blind randomised trial with a six month follow up. Gut 2003; 52: 40-46.
198. Moore RA. Helicobacter pylori and peptic ulcer: a systematic review of effectiveness and an overview of the economic benefits of implementing what is known to be effective. Oxford: Health Technology Evaluation Association, 1995.
199. Penston JG. Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Aliment Pharmacol Ther 1996; 10: 469-486.
200. Laine L, Hopkins RJ, Girardi LS. Has the impact of Heli-cobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93: 1.409-1.415.
201. Forman D, Bazzoli F, Bennett C, Broutet N, Calvet-Calvo X, Chiba N et al. Therapies for the eradication of Helicobacter pylori (Protocol for a Cochrane Review). En: The Cochrane Library, n.° 4, 2002. Oxford: Update Software.
202. Delaney B, Moayyedi P, Forman D. Helicobacter pylori infection. Clin Evid 2002; 7: 414-428.
203. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2.330-2.338.
204. Gisbert JP, Calvet X, Gomollón F, Sainz R. Conferencia de consenso. Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la Conferencia Española de Consenso. Med Clin (Barc) 2000; 114: 185-195.
205. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15: 1.949-1.958.
206. Gisbert JP, Boixeda D, de Argila CM, Bermejo F, Redondo C, de Rafael L. Erosive duodenitis: prevalence of Helicobacter pylori infection and response to eradication therapy with omeprazole plus two antibiotics. Eur J Gastroenterol Hepatol 1997; 9: 957-962.
207. Shiotani A, Nishioka S, Iguchi M, Yanaoka K, Okada K, Tamai H et al. Duodenal erosions after eradication of Helicobacter pylori infection. Gastrointest Endosc 2001; 54: 448-453.
208. Laine L, Cohen H, Sloane R, Marin-Sorensen M, Weinstein WM. Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers. Gastrointest Endosc 1995; 42: 420-423.
209. Vincze A, Karadi O, Hunyady B, Pakodi F, Suto G, Mozsik G. One year follow-up of patients after successful Helicobacter pylori eradication therapy. J Physiol Paris 2001; 95: 457-460.
210. Lehmann FS, Renner EL, Meyer-Wyss B, Wilder-Smith CH, Mazzucchelli L, Ruchti C et al. Helicobacter pylori and gastric erosions. Results of a prevalence study in asymptomatic volunteers. Digestion 2000; 62: 82-86.
211. Kate V, Ananthakrishnan N, Badrinath S, Amarnath SK, Balamurugan M, Ratnakar C. Helicobacter pylori infection and erosive gastritis. J Assoc Physicians India 1998; 46: 436-437.
212. Taha AS, Sturrock RD, Russell RI. Mucosal erosions in long-term non-steroidal anti-inflanunatory drug users: predisposition to ulceration and relation to Helicobacter pylori. Gut 1995; 36: 334-336.
213. Annibale B, Marignani M, Monarca B, Antonelli G, Marcheggiano A, Martino G et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med 1999; 131: 668-672.
214. Veldhuyzen van Zanten SJ, Sherman PM. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. CMAJ 1994; 150: 177-185.
215. McColl KE. The role of Helicobacter pylori eradication in the management of acute bleeding peptic ulcer. Eur J Gastroenterol Hepatol 1995; 7: 753-755.
216. Sharma VK, Sahai AV, Corder FA, Howden CW. Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage. Aliment Pharmacol Ther 2001; 15: 1.939-1.947.
217. Buring SM, Winner LH, Hatton RC, Doering PL. Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis. Pharmacotherapy 1999; 19: 324-332.
218. Penston JG, McColl KE. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-243.
219. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999; 13: 857-864.
220. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O'Morain C et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996; 1: 138-144.
221. Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741-746.
222. Wong BC, Wong WM, Yee YK, Hung WK, Yip AW, Szeto ML et al. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15: 1.959-1.965.
223. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002; 16: 1.933-1.938.
224. Veldhuyzen Van Zanten S, Lauritsen K, Delchier JC, Labenz J, De Argila CM, Lind T et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14: 1.605-1.611.
225. Tulassay Z, Kryszewski A, Dite P, Kleczkowski D, Rudzinski J, Bartuzi Z et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001; 13: 1.457-1.465.
226. Laine L. Esomeprazole in the treatment of Helicobacter pylori. Aliment Pharmacol Ther 2002; 16 (Supl. 4): 115-118.
227. Schmid CH, Whiting G, Cory D, Ross SD, Chalmers TC. Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: a meta-regression analysis of randomized, controlled trials. Am J Ther 1999; 6: 25-36.
228. Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 2002; 31: 128-139.
229. Jovell AJ, Aymerich M, García-Altés A, Serra-Prat M. Guia de pràctica clínica del tractament erradicador de la infecció per Helicobacter pylori associada a l'úlcera duodenal en l'atenció primària. Barcelona: Agència d'Avaluació de Tecnologia Mèdica. Servei Català de la Salut. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya: setembre de 1998.
230. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999; 13: 719-729.
231. Gisbert JP, Pajares JM. Resistencia de Helicobacter pylori al metronidazol y a la claritromicina en España. Una revisión sistemática. Med Clin (Barc) 2001; 116: 111-116.
232. Cuchf E, Forné M, Quintana S, Lite J, Garau J. Evolución de la sensibilidad de 235 cepas de Helicobacter pylori entre 1995 y 1998 e impacto del tratamiento antibiótico. Enferm Infecc Microbiol Clin 2002; 20: 157-160.
233. Gisbert JP, Calvet X, Bujanda L. Usefulness of 14-day rifabutin, amoxicillin and omeprazole triple therapy as a rescue therapy after multiple treatment failures. Helicobacter 2003 [en prensa].